A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma

Overview of attention for article published in American Journal of Hematology, December 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

news: 1 news outlet

twitter: 2 X users

Readers on

mendeley: 22 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,331 followers.

But with daratumumab NOT lenalidomide! A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma https://t.co/c5MB0wJMyM

New article: A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. https://t.co/yk9XVzYZFA #MMSM #MultipleMyeloma #hematology https://t.co/cJje1DszTd

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.